Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared on X:

“Adding nivolumab to neoadjuvant chemotherapy significantly increased pCR rates in high-risk, early-stage ER+/HER2− BC, particularly in patients with higher stromal tumor-infiltrating lymphocyte levels or programmed death ligand 1 expression.”

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial | Nature Medicine

Authors: Sherene Loi, Roberto Salgado, Giuseppe Curigliano, Roberto Iván Romero Díaz, Suzette Delaloge, Carlos Ignacio Rojas García, Marleen Kok, Cristina Saura, Nadia Harbeck, Elizabeth A. Mittendorf, Denise A. Yardley, Alberto Suárez Zaizar, Facundo Rufino Caminos, Andrei Ungureanu, Joaquin G. Reinoso-Toledo, Valentina Guarneri, Daniel Egle, Felipe Ades, Misena Pacius, Aparna Chhibber, Rajalakshmi Chandra, Raheel Nathani, Thomas Spires, Jenny Qun Wu, Lajos Pusztai, Heather McArthur

Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer